Table 2. Neonatal complications following induction in outpatient setting.

	NEONATAL COMPLICATIONS
PGE2 vaginal
Sawai 1991	0/24 in PGE2 group; 2/26 in placebo group to NICU
Sawai 1994	2/38 in PGE2; 4/42 in placebo group to NICU
O’Brien 1995	1/50 in PGE2; 5/50 in placebo group to NICU
TOTAL	3/112 PGE, 11/118 control to NICU
PGE2 intracervical
Larmon 2002	6/41 PGE group, 8/43 placebo group with complication such as tachypnea, meconium aspiration, meconium or admission to NICU
Magann 1998	3/35 PGE2 vs 0/35 control NICU admission
McKenna 1999	1/30 PGE, 2/31 placebo group with complication
TOTAL	10/106 PGE, 10/109 controls with neonatal complications/admitted to NICU
Vaginal misoprostol
Stitely 2000	1/27 misoprostol, 3/33 placebo group to NICU
Incerpi 2001	18/57 misoprostol, 20/63 placebo group to NICU
McKenna 2004	0/33 misoprostol, 1/35 placebo group to NICU
Oboro 2005	1/38 misoprostol, 1/39 control (no treatment) to NICU
TOTAL	20/155 misoprostol, 25/170 control to NICU
Misoprostol 25mcg versus 50mcg
Kipikasa 2005	1/23 25 mcg, 2/26 50 mcg misoprostol to NICU
Intracervical PGE2 versus intravaginal misoprostol
Meyer 2005	5/42 PGE, 4/42 misoprostol to NICU
Mifepristone
Elliott 1998	0/50 mifepristone, 1/30 placebo group to NICU
Giacalone 1998	5/41 mifepristone, 4/42 control to NICU
TOTAL	5/91 mifepristone, 5/72 control to NICU
IMN
Bollapragada 2006	18/177 IMN, 16/173 placebo group to NICU
Bullarbo 2007	13/100 IMN, 9/100 placebo group to NICU
Habib 2008	0/51 IMN, 1/51 placebo group to NICU
TOTAL	31/328 IMN, 26/324 placebo group to NICU

NICU: neonatal intensive-care unit